Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Parallelgruppenstudie zur Beurteilung der kardioprotektiven Wirkungen von Sotagliflozin auf die klinischen Ergebnisse bei hämodynamisch stabilen Patienten mit Typ-2-Diabetes NACH einer Verschlechterung der Herzinsuffizienz

Drug: Sotagliflozin (SAR439954);Drug: Placebo

Inclusion criteria:

- Type 2 Diabetes Mellitus.

- Admitted to the hospital, or urgent heart failure visit for worsening heart failure.

- Prior diagnosis of heart failure (> 3 months).

- Prior chronic treatment for heart failure with a loop diuretic (eg furosemide,
torsemide, bumetanide) for > 30 days.

- Randomized when hemodynamically stable, prior to hospital discharge or within 3 days
of discharge.

- Brain natriuretic peptide (BNP) =150 pg/mL (=450 pg/mL for patients with atrial
fibrillation) or N-terminal B-type natriuretic peptide =600 pg/mL (=1800 pg/mL for
patients with atrial fibrillation).

- Patients with Left Ventricular Ejection Fraction <40% should be on beta-blockers and
renin-angiotensin-aldosterone system (RAAS) inhibitors as per local guidelines unless
contraindicated.

- Signed written informed consent.

Exclusion criteria:

- Age < 18 years or > 85 years.

- Worsening heart failure attributed to other causes such as pulmonary embolism, stroke,
heart attack.

- Cardiac surgery or coronary procedure within 1 month or planned during study.

- Lower extremity complications (such as skin ulcer, infection, osteomyelitis, and
gangrene) identified during screening and requiring treatment at randomization.

- Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during the
study.

- Acute coronary syndromes within 3 months prior to Randomization.

- Hemodynamically significant uncorrected primary valvular disease.

- Significant pulmonary disease contributing substantially to the patient's dyspnea.

- End stage Heart Failure.

- History of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar coma within 3 months
prior to screening.

- History of stroke within 3 months prior to randomization.

- History of dialysis within 1 year prior to randomization.

- History of solid organ transplant or on a transplant list (if heart transplant,
defined as status 1 transplant).

- Severe kidney disease as defined by glomerular filtration rate (eGFR) <30 mL/min/1.73
m².

- Pregnancy.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.